Revance Therapeutics Inc
RVNC
Market Cap$447.08M
Close$
$6.05
82.7% upside
Current Fair Value
82.7% upsideUndervalued by 82.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $447.08 Million |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $0.0 |
| Beta | 2.05 |
| Outstanding Shares | 104,215,614 |
| Avg 30 Day Volume | 1,815,190 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 0.0 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
ESG Score
No data
About Revance Therapeutics Inc
CEO: Mark Foley